Datasets:

nzindoc

/

dataset-multiple-myeloma

like 0

The impact of patient characteristics on the median PFS for Velcade Melphalan-Prednisone (VMP).

The median progression-free survival (PFS) for the treatment combination of Velcade Melphalan-Prednisone (VMP) from ALCYONE was 18.1 months with a 95% Confidence Interval (CI) of (16.5, 19.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Velcade Melphalan-Prednisone (VMP). ### Response: The median progression-free survival (PFS) for the treatment combination of Velcade Melphalan-Prednisone (VMP) from ALCYONE was 18.1 months with a 95% Confidence Interval (CI) of (16.5, 19.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

The role of genetic factors in the median PFS for Velcade Melphalan-Prednisone (VMP).

The median progression-free survival (PFS) for the treatment combination of Velcade Melphalan-Prednisone (VMP) from ALCYONE was 18.1 months with a 95% Confidence Interval (CI) of (16.5, 19.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Velcade Melphalan-Prednisone (VMP). ### Response: The median progression-free survival (PFS) for the treatment combination of Velcade Melphalan-Prednisone (VMP) from ALCYONE was 18.1 months with a 95% Confidence Interval (CI) of (16.5, 19.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

The influence of previous treatments on the median PFS for Velcade Melphalan-Prednisone (VMP).

The median progression-free survival (PFS) for the treatment combination of Velcade Melphalan-Prednisone (VMP) from ALCYONE was 18.1 months with a 95% Confidence Interval (CI) of (16.5, 19.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Velcade Melphalan-Prednisone (VMP). ### Response: The median progression-free survival (PFS) for the treatment combination of Velcade Melphalan-Prednisone (VMP) from ALCYONE was 18.1 months with a 95% Confidence Interval (CI) of (16.5, 19.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

The effect of dosage and administration frequency on the median PFS for Velcade Melphalan-Prednisone (VMP).

The median progression-free survival (PFS) for the treatment combination of Velcade Melphalan-Prednisone (VMP) from ALCYONE was 18.1 months with a 95% Confidence Interval (CI) of (16.5, 19.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Velcade Melphalan-Prednisone (VMP). ### Response: The median progression-free survival (PFS) for the treatment combination of Velcade Melphalan-Prednisone (VMP) from ALCYONE was 18.1 months with a 95% Confidence Interval (CI) of (16.5, 19.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

The correlation between the median PFS for Velcade Melphalan-Prednisone (VMP) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Velcade Melphalan-Prednisone (VMP) from ALCYONE was 18.1 months with a 95% Confidence Interval (CI) of (16.5, 19.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Velcade Melphalan-Prednisone (VMP) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Velcade Melphalan-Prednisone (VMP) from ALCYONE was 18.1 months with a 95% Confidence Interval (CI) of (16.5, 19.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

The impact of side effects and adverse reactions on the median PFS for Velcade Melphalan-Prednisone (VMP).

The median progression-free survival (PFS) for the treatment combination of Velcade Melphalan-Prednisone (VMP) from ALCYONE was 18.1 months with a 95% Confidence Interval (CI) of (16.5, 19.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Velcade Melphalan-Prednisone (VMP). ### Response: The median progression-free survival (PFS) for the treatment combination of Velcade Melphalan-Prednisone (VMP) from ALCYONE was 18.1 months with a 95% Confidence Interval (CI) of (16.5, 19.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

The role of supportive care in improving the median PFS for Velcade Melphalan-Prednisone (VMP).

The median progression-free survival (PFS) for the treatment combination of Velcade Melphalan-Prednisone (VMP) from ALCYONE was 18.1 months with a 95% Confidence Interval (CI) of (16.5, 19.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Velcade Melphalan-Prednisone (VMP). ### Response: The median progression-free survival (PFS) for the treatment combination of Velcade Melphalan-Prednisone (VMP) from ALCYONE was 18.1 months with a 95% Confidence Interval (CI) of (16.5, 19.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

The influence of disease stage at the start of treatment on the median PFS for Velcade Melphalan-Prednisone (VMP).

The median progression-free survival (PFS) for the treatment combination of Velcade Melphalan-Prednisone (VMP) from ALCYONE was 18.1 months with a 95% Confidence Interval (CI) of (16.5, 19.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Velcade Melphalan-Prednisone (VMP). ### Response: The median progression-free survival (PFS) for the treatment combination of Velcade Melphalan-Prednisone (VMP) from ALCYONE was 18.1 months with a 95% Confidence Interval (CI) of (16.5, 19.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

The effect of concurrent health conditions on the median PFS for Velcade Melphalan-Prednisone (VMP).

The median progression-free survival (PFS) for the treatment combination of Velcade Melphalan-Prednisone (VMP) from ALCYONE was 18.1 months with a 95% Confidence Interval (CI) of (16.5, 19.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Velcade Melphalan-Prednisone (VMP). ### Response: The median progression-free survival (PFS) for the treatment combination of Velcade Melphalan-Prednisone (VMP) from ALCYONE was 18.1 months with a 95% Confidence Interval (CI) of (16.5, 19.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1714678)}

Median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd)?

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from MAIA was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd)? ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from MAIA was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

Comparison of the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from MAIA was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from MAIA was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

The impact of patient characteristics on the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from MAIA was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from MAIA was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

The role of genetic factors in the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from MAIA was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from MAIA was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

The influence of previous treatments on the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from MAIA was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from MAIA was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

The effect of dosage and administration frequency on the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from MAIA was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from MAIA was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

The correlation between the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from MAIA was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from MAIA was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

The impact of side effects and adverse reactions on the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from MAIA was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from MAIA was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

The role of supportive care in improving the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from MAIA was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from MAIA was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

The influence of disease stage at the start of treatment on the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from MAIA was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from MAIA was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

The effect of concurrent health conditions on the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd).

The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from MAIA was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd). ### Response: The median progression-free survival (PFS) for the treatment combination of Daratumumab+Lenalidomide+Dexamethasone (DRd) from MAIA was NR months with a 95% Confidence Interval (CI) of None ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

Median PFS for Lenalidomide And Dexamethasone (Rd)?

The median progression-free survival (PFS) for the treatment combination of Lenalidomide And Dexamethasone (Rd) from MAIA was 34.4 months with a 95% Confidence Interval (CI) of (29.6, 39.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Lenalidomide And Dexamethasone (Rd)? ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide And Dexamethasone (Rd) from MAIA was 34.4 months with a 95% Confidence Interval (CI) of (29.6, 39.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

Comparison of the median PFS for Lenalidomide And Dexamethasone (Rd) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Lenalidomide And Dexamethasone (Rd) from MAIA was 34.4 months with a 95% Confidence Interval (CI) of (29.6, 39.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Lenalidomide And Dexamethasone (Rd) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide And Dexamethasone (Rd) from MAIA was 34.4 months with a 95% Confidence Interval (CI) of (29.6, 39.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

The impact of patient characteristics on the median PFS for Lenalidomide And Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide And Dexamethasone (Rd) from MAIA was 34.4 months with a 95% Confidence Interval (CI) of (29.6, 39.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Lenalidomide And Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide And Dexamethasone (Rd) from MAIA was 34.4 months with a 95% Confidence Interval (CI) of (29.6, 39.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

The role of genetic factors in the median PFS for Lenalidomide And Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide And Dexamethasone (Rd) from MAIA was 34.4 months with a 95% Confidence Interval (CI) of (29.6, 39.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Lenalidomide And Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide And Dexamethasone (Rd) from MAIA was 34.4 months with a 95% Confidence Interval (CI) of (29.6, 39.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

The influence of previous treatments on the median PFS for Lenalidomide And Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide And Dexamethasone (Rd) from MAIA was 34.4 months with a 95% Confidence Interval (CI) of (29.6, 39.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Lenalidomide And Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide And Dexamethasone (Rd) from MAIA was 34.4 months with a 95% Confidence Interval (CI) of (29.6, 39.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

The effect of dosage and administration frequency on the median PFS for Lenalidomide And Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide And Dexamethasone (Rd) from MAIA was 34.4 months with a 95% Confidence Interval (CI) of (29.6, 39.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Lenalidomide And Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide And Dexamethasone (Rd) from MAIA was 34.4 months with a 95% Confidence Interval (CI) of (29.6, 39.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

The correlation between the median PFS for Lenalidomide And Dexamethasone (Rd) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Lenalidomide And Dexamethasone (Rd) from MAIA was 34.4 months with a 95% Confidence Interval (CI) of (29.6, 39.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Lenalidomide And Dexamethasone (Rd) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide And Dexamethasone (Rd) from MAIA was 34.4 months with a 95% Confidence Interval (CI) of (29.6, 39.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

The impact of side effects and adverse reactions on the median PFS for Lenalidomide And Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide And Dexamethasone (Rd) from MAIA was 34.4 months with a 95% Confidence Interval (CI) of (29.6, 39.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Lenalidomide And Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide And Dexamethasone (Rd) from MAIA was 34.4 months with a 95% Confidence Interval (CI) of (29.6, 39.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

The role of supportive care in improving the median PFS for Lenalidomide And Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide And Dexamethasone (Rd) from MAIA was 34.4 months with a 95% Confidence Interval (CI) of (29.6, 39.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Lenalidomide And Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide And Dexamethasone (Rd) from MAIA was 34.4 months with a 95% Confidence Interval (CI) of (29.6, 39.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

The influence of disease stage at the start of treatment on the median PFS for Lenalidomide And Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide And Dexamethasone (Rd) from MAIA was 34.4 months with a 95% Confidence Interval (CI) of (29.6, 39.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Lenalidomide And Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide And Dexamethasone (Rd) from MAIA was 34.4 months with a 95% Confidence Interval (CI) of (29.6, 39.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

The effect of concurrent health conditions on the median PFS for Lenalidomide And Dexamethasone (Rd).

The median progression-free survival (PFS) for the treatment combination of Lenalidomide And Dexamethasone (Rd) from MAIA was 34.4 months with a 95% Confidence Interval (CI) of (29.6, 39.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Lenalidomide And Dexamethasone (Rd). ### Response: The median progression-free survival (PFS) for the treatment combination of Lenalidomide And Dexamethasone (Rd) from MAIA was 34.4 months with a 95% Confidence Interval (CI) of (29.6, 39.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/fulltext)}

Median PFS for Selinexor+Dexamethasone (Sd)?

The median progression-free survival (PFS) for the treatment combination of Selinexor+Dexamethasone (Sd) from STORM was 3.7 months with a 95% Confidence Interval (CI) of (3, 5.3) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1903455)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Selinexor+Dexamethasone (Sd)? ### Response: The median progression-free survival (PFS) for the treatment combination of Selinexor+Dexamethasone (Sd) from STORM was 3.7 months with a 95% Confidence Interval (CI) of (3, 5.3) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1903455)}

Comparison of the median PFS for Selinexor+Dexamethasone (Sd) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Selinexor+Dexamethasone (Sd) from STORM was 3.7 months with a 95% Confidence Interval (CI) of (3, 5.3) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1903455)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Selinexor+Dexamethasone (Sd) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Selinexor+Dexamethasone (Sd) from STORM was 3.7 months with a 95% Confidence Interval (CI) of (3, 5.3) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1903455)}

The impact of patient characteristics on the median PFS for Selinexor+Dexamethasone (Sd).

The median progression-free survival (PFS) for the treatment combination of Selinexor+Dexamethasone (Sd) from STORM was 3.7 months with a 95% Confidence Interval (CI) of (3, 5.3) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1903455)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Selinexor+Dexamethasone (Sd). ### Response: The median progression-free survival (PFS) for the treatment combination of Selinexor+Dexamethasone (Sd) from STORM was 3.7 months with a 95% Confidence Interval (CI) of (3, 5.3) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1903455)}

The role of genetic factors in the median PFS for Selinexor+Dexamethasone (Sd).

The median progression-free survival (PFS) for the treatment combination of Selinexor+Dexamethasone (Sd) from STORM was 3.7 months with a 95% Confidence Interval (CI) of (3, 5.3) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1903455)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Selinexor+Dexamethasone (Sd). ### Response: The median progression-free survival (PFS) for the treatment combination of Selinexor+Dexamethasone (Sd) from STORM was 3.7 months with a 95% Confidence Interval (CI) of (3, 5.3) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1903455)}

The influence of previous treatments on the median PFS for Selinexor+Dexamethasone (Sd).

The median progression-free survival (PFS) for the treatment combination of Selinexor+Dexamethasone (Sd) from STORM was 3.7 months with a 95% Confidence Interval (CI) of (3, 5.3) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1903455)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Selinexor+Dexamethasone (Sd). ### Response: The median progression-free survival (PFS) for the treatment combination of Selinexor+Dexamethasone (Sd) from STORM was 3.7 months with a 95% Confidence Interval (CI) of (3, 5.3) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1903455)}

The effect of dosage and administration frequency on the median PFS for Selinexor+Dexamethasone (Sd).

The median progression-free survival (PFS) for the treatment combination of Selinexor+Dexamethasone (Sd) from STORM was 3.7 months with a 95% Confidence Interval (CI) of (3, 5.3) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1903455)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Selinexor+Dexamethasone (Sd). ### Response: The median progression-free survival (PFS) for the treatment combination of Selinexor+Dexamethasone (Sd) from STORM was 3.7 months with a 95% Confidence Interval (CI) of (3, 5.3) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1903455)}

The correlation between the median PFS for Selinexor+Dexamethasone (Sd) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Selinexor+Dexamethasone (Sd) from STORM was 3.7 months with a 95% Confidence Interval (CI) of (3, 5.3) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1903455)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Selinexor+Dexamethasone (Sd) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Selinexor+Dexamethasone (Sd) from STORM was 3.7 months with a 95% Confidence Interval (CI) of (3, 5.3) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1903455)}

The impact of side effects and adverse reactions on the median PFS for Selinexor+Dexamethasone (Sd).

The median progression-free survival (PFS) for the treatment combination of Selinexor+Dexamethasone (Sd) from STORM was 3.7 months with a 95% Confidence Interval (CI) of (3, 5.3) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1903455)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Selinexor+Dexamethasone (Sd). ### Response: The median progression-free survival (PFS) for the treatment combination of Selinexor+Dexamethasone (Sd) from STORM was 3.7 months with a 95% Confidence Interval (CI) of (3, 5.3) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1903455)}

The role of supportive care in improving the median PFS for Selinexor+Dexamethasone (Sd).

The median progression-free survival (PFS) for the treatment combination of Selinexor+Dexamethasone (Sd) from STORM was 3.7 months with a 95% Confidence Interval (CI) of (3, 5.3) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1903455)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Selinexor+Dexamethasone (Sd). ### Response: The median progression-free survival (PFS) for the treatment combination of Selinexor+Dexamethasone (Sd) from STORM was 3.7 months with a 95% Confidence Interval (CI) of (3, 5.3) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1903455)}

The influence of disease stage at the start of treatment on the median PFS for Selinexor+Dexamethasone (Sd).

The median progression-free survival (PFS) for the treatment combination of Selinexor+Dexamethasone (Sd) from STORM was 3.7 months with a 95% Confidence Interval (CI) of (3, 5.3) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1903455)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Selinexor+Dexamethasone (Sd). ### Response: The median progression-free survival (PFS) for the treatment combination of Selinexor+Dexamethasone (Sd) from STORM was 3.7 months with a 95% Confidence Interval (CI) of (3, 5.3) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1903455)}

The effect of concurrent health conditions on the median PFS for Selinexor+Dexamethasone (Sd).

The median progression-free survival (PFS) for the treatment combination of Selinexor+Dexamethasone (Sd) from STORM was 3.7 months with a 95% Confidence Interval (CI) of (3, 5.3) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1903455)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Selinexor+Dexamethasone (Sd). ### Response: The median progression-free survival (PFS) for the treatment combination of Selinexor+Dexamethasone (Sd) from STORM was 3.7 months with a 95% Confidence Interval (CI) of (3, 5.3) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1903455)}

Median PFS for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone?

The median progression-free survival (PFS) for the treatment combination of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone from ARROW was 11.2 months with a 95% Confidence Interval (CI) of (8.6, 13.0) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone? ### Response: The median progression-free survival (PFS) for the treatment combination of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone from ARROW was 11.2 months with a 95% Confidence Interval (CI) of (8.6, 13.0) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

Comparison of the median PFS for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone from ARROW was 11.2 months with a 95% Confidence Interval (CI) of (8.6, 13.0) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone from ARROW was 11.2 months with a 95% Confidence Interval (CI) of (8.6, 13.0) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

The impact of patient characteristics on the median PFS for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone.

The median progression-free survival (PFS) for the treatment combination of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone from ARROW was 11.2 months with a 95% Confidence Interval (CI) of (8.6, 13.0) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone. ### Response: The median progression-free survival (PFS) for the treatment combination of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone from ARROW was 11.2 months with a 95% Confidence Interval (CI) of (8.6, 13.0) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

The role of genetic factors in the median PFS for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone.

The median progression-free survival (PFS) for the treatment combination of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone from ARROW was 11.2 months with a 95% Confidence Interval (CI) of (8.6, 13.0) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone. ### Response: The median progression-free survival (PFS) for the treatment combination of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone from ARROW was 11.2 months with a 95% Confidence Interval (CI) of (8.6, 13.0) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

The influence of previous treatments on the median PFS for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone.

The median progression-free survival (PFS) for the treatment combination of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone from ARROW was 11.2 months with a 95% Confidence Interval (CI) of (8.6, 13.0) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone. ### Response: The median progression-free survival (PFS) for the treatment combination of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone from ARROW was 11.2 months with a 95% Confidence Interval (CI) of (8.6, 13.0) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

The effect of dosage and administration frequency on the median PFS for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone.

The median progression-free survival (PFS) for the treatment combination of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone from ARROW was 11.2 months with a 95% Confidence Interval (CI) of (8.6, 13.0) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone. ### Response: The median progression-free survival (PFS) for the treatment combination of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone from ARROW was 11.2 months with a 95% Confidence Interval (CI) of (8.6, 13.0) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

The correlation between the median PFS for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone from ARROW was 11.2 months with a 95% Confidence Interval (CI) of (8.6, 13.0) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone from ARROW was 11.2 months with a 95% Confidence Interval (CI) of (8.6, 13.0) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

The impact of side effects and adverse reactions on the median PFS for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone.

The median progression-free survival (PFS) for the treatment combination of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone from ARROW was 11.2 months with a 95% Confidence Interval (CI) of (8.6, 13.0) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone. ### Response: The median progression-free survival (PFS) for the treatment combination of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone from ARROW was 11.2 months with a 95% Confidence Interval (CI) of (8.6, 13.0) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

The role of supportive care in improving the median PFS for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone.

The median progression-free survival (PFS) for the treatment combination of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone from ARROW was 11.2 months with a 95% Confidence Interval (CI) of (8.6, 13.0) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone. ### Response: The median progression-free survival (PFS) for the treatment combination of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone from ARROW was 11.2 months with a 95% Confidence Interval (CI) of (8.6, 13.0) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

The influence of disease stage at the start of treatment on the median PFS for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone.

The median progression-free survival (PFS) for the treatment combination of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone from ARROW was 11.2 months with a 95% Confidence Interval (CI) of (8.6, 13.0) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone. ### Response: The median progression-free survival (PFS) for the treatment combination of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone from ARROW was 11.2 months with a 95% Confidence Interval (CI) of (8.6, 13.0) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

The effect of concurrent health conditions on the median PFS for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone.

The median progression-free survival (PFS) for the treatment combination of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone from ARROW was 11.2 months with a 95% Confidence Interval (CI) of (8.6, 13.0) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone. ### Response: The median progression-free survival (PFS) for the treatment combination of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone from ARROW was 11.2 months with a 95% Confidence Interval (CI) of (8.6, 13.0) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

Median PFS for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone?

The median progression-free survival (PFS) for the treatment combination of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone from ARROW was 7.6 months with a 95% Confidence Interval (CI) of (5.8, 9.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone? ### Response: The median progression-free survival (PFS) for the treatment combination of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone from ARROW was 7.6 months with a 95% Confidence Interval (CI) of (5.8, 9.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

Comparison of the median PFS for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone from ARROW was 7.6 months with a 95% Confidence Interval (CI) of (5.8, 9.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone from ARROW was 7.6 months with a 95% Confidence Interval (CI) of (5.8, 9.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

The impact of patient characteristics on the median PFS for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone.

The median progression-free survival (PFS) for the treatment combination of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone from ARROW was 7.6 months with a 95% Confidence Interval (CI) of (5.8, 9.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone. ### Response: The median progression-free survival (PFS) for the treatment combination of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone from ARROW was 7.6 months with a 95% Confidence Interval (CI) of (5.8, 9.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

The role of genetic factors in the median PFS for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone.

The median progression-free survival (PFS) for the treatment combination of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone from ARROW was 7.6 months with a 95% Confidence Interval (CI) of (5.8, 9.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone. ### Response: The median progression-free survival (PFS) for the treatment combination of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone from ARROW was 7.6 months with a 95% Confidence Interval (CI) of (5.8, 9.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

The influence of previous treatments on the median PFS for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone.

The median progression-free survival (PFS) for the treatment combination of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone from ARROW was 7.6 months with a 95% Confidence Interval (CI) of (5.8, 9.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone. ### Response: The median progression-free survival (PFS) for the treatment combination of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone from ARROW was 7.6 months with a 95% Confidence Interval (CI) of (5.8, 9.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

The effect of dosage and administration frequency on the median PFS for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone.

The median progression-free survival (PFS) for the treatment combination of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone from ARROW was 7.6 months with a 95% Confidence Interval (CI) of (5.8, 9.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone. ### Response: The median progression-free survival (PFS) for the treatment combination of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone from ARROW was 7.6 months with a 95% Confidence Interval (CI) of (5.8, 9.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

The correlation between the median PFS for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone from ARROW was 7.6 months with a 95% Confidence Interval (CI) of (5.8, 9.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone from ARROW was 7.6 months with a 95% Confidence Interval (CI) of (5.8, 9.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

The impact of side effects and adverse reactions on the median PFS for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone.

The median progression-free survival (PFS) for the treatment combination of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone from ARROW was 7.6 months with a 95% Confidence Interval (CI) of (5.8, 9.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone. ### Response: The median progression-free survival (PFS) for the treatment combination of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone from ARROW was 7.6 months with a 95% Confidence Interval (CI) of (5.8, 9.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

The role of supportive care in improving the median PFS for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone.

The median progression-free survival (PFS) for the treatment combination of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone from ARROW was 7.6 months with a 95% Confidence Interval (CI) of (5.8, 9.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone. ### Response: The median progression-free survival (PFS) for the treatment combination of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone from ARROW was 7.6 months with a 95% Confidence Interval (CI) of (5.8, 9.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

The influence of disease stage at the start of treatment on the median PFS for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone.

The median progression-free survival (PFS) for the treatment combination of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone from ARROW was 7.6 months with a 95% Confidence Interval (CI) of (5.8, 9.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone. ### Response: The median progression-free survival (PFS) for the treatment combination of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone from ARROW was 7.6 months with a 95% Confidence Interval (CI) of (5.8, 9.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

The effect of concurrent health conditions on the median PFS for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone.

The median progression-free survival (PFS) for the treatment combination of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone from ARROW was 7.6 months with a 95% Confidence Interval (CI) of (5.8, 9.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone. ### Response: The median progression-free survival (PFS) for the treatment combination of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone from ARROW was 7.6 months with a 95% Confidence Interval (CI) of (5.8, 9.2) ^{[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext)}

Median PFS for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd)?

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd)? ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Comparison of the median PFS for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The impact of patient characteristics on the median PFS for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The role of genetic factors in the median PFS for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The influence of previous treatments on the median PFS for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The effect of dosage and administration frequency on the median PFS for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The correlation between the median PFS for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The impact of side effects and adverse reactions on the median PFS for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The role of supportive care in improving the median PFS for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The influence of disease stage at the start of treatment on the median PFS for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The effect of concurrent health conditions on the median PFS for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Median PFS for Bortezomib+Thalidomide+Dexamethasone (VTd)?

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone (VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Bortezomib+Thalidomide+Dexamethasone (VTd)? ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone (VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Comparison of the median PFS for Bortezomib+Thalidomide+Dexamethasone (VTd) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone (VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Bortezomib+Thalidomide+Dexamethasone (VTd) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone (VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The impact of patient characteristics on the median PFS for Bortezomib+Thalidomide+Dexamethasone (VTd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone (VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Bortezomib+Thalidomide+Dexamethasone (VTd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone (VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The role of genetic factors in the median PFS for Bortezomib+Thalidomide+Dexamethasone (VTd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone (VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Bortezomib+Thalidomide+Dexamethasone (VTd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone (VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The influence of previous treatments on the median PFS for Bortezomib+Thalidomide+Dexamethasone (VTd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone (VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Bortezomib+Thalidomide+Dexamethasone (VTd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone (VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The effect of dosage and administration frequency on the median PFS for Bortezomib+Thalidomide+Dexamethasone (VTd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone (VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Bortezomib+Thalidomide+Dexamethasone (VTd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone (VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The correlation between the median PFS for Bortezomib+Thalidomide+Dexamethasone (VTd) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone (VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Bortezomib+Thalidomide+Dexamethasone (VTd) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone (VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The impact of side effects and adverse reactions on the median PFS for Bortezomib+Thalidomide+Dexamethasone (VTd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone (VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Bortezomib+Thalidomide+Dexamethasone (VTd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone (VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The role of supportive care in improving the median PFS for Bortezomib+Thalidomide+Dexamethasone (VTd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone (VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Bortezomib+Thalidomide+Dexamethasone (VTd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone (VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The influence of disease stage at the start of treatment on the median PFS for Bortezomib+Thalidomide+Dexamethasone (VTd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone (VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Bortezomib+Thalidomide+Dexamethasone (VTd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone (VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

The effect of concurrent health conditions on the median PFS for Bortezomib+Thalidomide+Dexamethasone (VTd).

The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone (VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Bortezomib+Thalidomide+Dexamethasone (VTd). ### Response: The median progression-free survival (PFS) for the treatment combination of Bortezomib+Thalidomide+Dexamethasone (VTd) from CASSIOPEIA was NR months with a 95% Confidence Interval (CI) of NR ^{[1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31240-1/fulltext)}

Median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd)?

The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from ELOQUENT-3 was 10.3 months with a 95% Confidence Interval (CI) of (5.6, NE) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1805762)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd)? ### Response: The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from ELOQUENT-3 was 10.3 months with a 95% Confidence Interval (CI) of (5.6, NE) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1805762)}

Comparison of the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from ELOQUENT-3 was 10.3 months with a 95% Confidence Interval (CI) of (5.6, NE) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1805762)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from ELOQUENT-3 was 10.3 months with a 95% Confidence Interval (CI) of (5.6, NE) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1805762)}

The impact of patient characteristics on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd).

The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from ELOQUENT-3 was 10.3 months with a 95% Confidence Interval (CI) of (5.6, NE) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1805762)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd). ### Response: The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from ELOQUENT-3 was 10.3 months with a 95% Confidence Interval (CI) of (5.6, NE) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1805762)}

The role of genetic factors in the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd).

The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from ELOQUENT-3 was 10.3 months with a 95% Confidence Interval (CI) of (5.6, NE) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1805762)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd). ### Response: The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from ELOQUENT-3 was 10.3 months with a 95% Confidence Interval (CI) of (5.6, NE) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1805762)}

The influence of previous treatments on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd).

The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from ELOQUENT-3 was 10.3 months with a 95% Confidence Interval (CI) of (5.6, NE) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1805762)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd). ### Response: The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from ELOQUENT-3 was 10.3 months with a 95% Confidence Interval (CI) of (5.6, NE) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1805762)}

The effect of dosage and administration frequency on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd).

The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from ELOQUENT-3 was 10.3 months with a 95% Confidence Interval (CI) of (5.6, NE) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1805762)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd). ### Response: The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from ELOQUENT-3 was 10.3 months with a 95% Confidence Interval (CI) of (5.6, NE) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1805762)}

The correlation between the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from ELOQUENT-3 was 10.3 months with a 95% Confidence Interval (CI) of (5.6, NE) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1805762)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from ELOQUENT-3 was 10.3 months with a 95% Confidence Interval (CI) of (5.6, NE) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1805762)}

The impact of side effects and adverse reactions on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd).

The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from ELOQUENT-3 was 10.3 months with a 95% Confidence Interval (CI) of (5.6, NE) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1805762)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd). ### Response: The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from ELOQUENT-3 was 10.3 months with a 95% Confidence Interval (CI) of (5.6, NE) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1805762)}

The role of supportive care in improving the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd).

The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from ELOQUENT-3 was 10.3 months with a 95% Confidence Interval (CI) of (5.6, NE) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1805762)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd). ### Response: The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from ELOQUENT-3 was 10.3 months with a 95% Confidence Interval (CI) of (5.6, NE) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1805762)}

The influence of disease stage at the start of treatment on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd).

The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from ELOQUENT-3 was 10.3 months with a 95% Confidence Interval (CI) of (5.6, NE) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1805762)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd). ### Response: The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from ELOQUENT-3 was 10.3 months with a 95% Confidence Interval (CI) of (5.6, NE) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1805762)}

The effect of concurrent health conditions on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd).

The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from ELOQUENT-3 was 10.3 months with a 95% Confidence Interval (CI) of (5.6, NE) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1805762)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd). ### Response: The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from ELOQUENT-3 was 10.3 months with a 95% Confidence Interval (CI) of (5.6, NE) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1805762)}

Median PFS for Pomalidomide+Dexamethasone (Pd)?

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone (Pd) from ELOQUENT-3 was 4.7 months with a 95% Confidence Interval (CI) of (2.8, 7.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1805762)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Pomalidomide+Dexamethasone (Pd)? ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone (Pd) from ELOQUENT-3 was 4.7 months with a 95% Confidence Interval (CI) of (2.8, 7.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1805762)}

Comparison of the median PFS for Pomalidomide+Dexamethasone (Pd) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone (Pd) from ELOQUENT-3 was 4.7 months with a 95% Confidence Interval (CI) of (2.8, 7.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1805762)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Pomalidomide+Dexamethasone (Pd) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone (Pd) from ELOQUENT-3 was 4.7 months with a 95% Confidence Interval (CI) of (2.8, 7.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1805762)}

The impact of patient characteristics on the median PFS for Pomalidomide+Dexamethasone (Pd).

The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone (Pd) from ELOQUENT-3 was 4.7 months with a 95% Confidence Interval (CI) of (2.8, 7.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1805762)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Pomalidomide+Dexamethasone (Pd). ### Response: The median progression-free survival (PFS) for the treatment combination of Pomalidomide+Dexamethasone (Pd) from ELOQUENT-3 was 4.7 months with a 95% Confidence Interval (CI) of (2.8, 7.2) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa1805762)}